RETRACTED ARTICLE: Ramosetronvs granisetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy

  • Yoshitaka Fujii
  • Yuhji Saitoh
  • Hiroyoshi Tanaka
  • Hidenori Toyooka
Brief Report



To compare the efficacy of ramosetron with granisetron for the prevention of postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy.


In a randomized, double-blind study, 80 female inpatients received 3 mg granisetron or 0.3 mg ramosetroniv (n=40 of each) at the completion of surgery The standardized anesthetic included isoflurane and nitrous oxide in oxygen.


Complete response, defined as no PONV during the first 24 hr (0–24 hr) after anesthesia was 85% with granisetron and 93% with ramosetron, respectively (P=0.241); the corresponding incidence during the next 24 hr (24–48 hr) after anesthesia was 63% and 90% (P=0.004). No clinically important adverse events due to the study drug were observed in any of the groups.


Ramosetron was more effective than granisetron for prevention of PONV during 0–48 hr after anesthesia for laparoscopic cholecystectomy.


Laparoscopic Cholecystectomy Granisetron Droperidol Motion Sickness Antiemetic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Comparer l’efficacité du ramosétron et du granisétron dans la prévention des nausées et des vomissements postopératoires (NVPO) à la suite d’une cholécystectomie laparoscopique.


L’étude randomisée, à double insu, a porté sur 80 femmes qui ont reçu 3 mg de granisétron ou 0,3 mg de ramosétroniv (n=40 dans chaque cas) après l’opération. Lanesthésie standard comprenait de l’isoflurane et un mélange de protoxyde d’azote et d’oxygène.


La réponse complète, définie comme une absence de NVPO, a été de 85% avec le granisétron et de 93% avec le ramosétron, respectivement (P=0,241), pendant les 24 premières heures postanesthésiques (0–24 h); pendant les 24 h suivantes, l’incidence correspondante a été de 63% et de 90% (P=0,004). Aucun événement indésirable, d’importance clinique et relié aux médicaments de l’étude, n’est survenu.


Le ramosétron a été plus efficace que le granisétron à prévenir les NVPO pendant les 48 premières heures qui ont suivi la cholécystectomie laparoscopique.


  1. 1.
    Fujii Y, Tanaka H, Toyooka H. Granisetron reduces the incidence and severity of nausea and vomiting after laparoscopic cholecystectomy. Can J Anaesth 1997; 44: 396–400.PubMedCrossRefGoogle Scholar
  2. 2.
    Fujii Y, Saitoh Y, Tanaka H, Toyooka H. Anti-emetic efficacy of prophylactic graniserton, droperidol and metoclopramide in the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled trial. Eur J Anesthesiol 1988; 15: 166–71.Google Scholar
  3. 3.
    Fujibara A, Akuzawa S, Miyata K, Miyake A. Ramosetron hydrochloride: affinity for cloned human 5-HT3 receptor and 5-HT3 receptor antagonistic and antiemetic effect in the ferret. (Japanese) Kiso to Rinsho 1996; 30: 1965–72.Google Scholar
  4. 4.
    Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Bermudez J, Boyle EA, Minter WD, Sanger GJ. The antiemetic potential of the 5hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 1988; 58: 644–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989; 24: 45–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Noda K, Ikeda M, Yoshida O, et al. Clinical evaluation of ramosetron against the nausea and vomiting induced by anticancer drugs. (Japanese) Jpn J Clin Exp Med 1994; 71: 2765–76.Google Scholar

Copyright information

© Canadian Anesthesiologists 1999

Authors and Affiliations

  • Yoshitaka Fujii
    • 1
  • Yuhji Saitoh
    • 2
  • Hiroyoshi Tanaka
    • 2
  • Hidenori Toyooka
    • 1
  1. 1.Department of AnaesthesiologyUniversity of Tsukuba Institute of Clinical MedicineIbarakiJapan
  2. 2.Department of AnaesthesiologyToride Kyodo General HospitalIbarakiJapan

Personalised recommendations